CA2075982A1 - Insulin compositions - Google Patents

Insulin compositions

Info

Publication number
CA2075982A1
CA2075982A1 CA002075982A CA2075982A CA2075982A1 CA 2075982 A1 CA2075982 A1 CA 2075982A1 CA 002075982 A CA002075982 A CA 002075982A CA 2075982 A CA2075982 A CA 2075982A CA 2075982 A1 CA2075982 A1 CA 2075982A1
Authority
CA
Canada
Prior art keywords
insulin
iii
ins
general formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002075982A
Other languages
English (en)
French (fr)
Inventor
Jorgen F. Hansen
Ulla Ribel-Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2075982A1 publication Critical patent/CA2075982A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Chairs For Special Purposes, Such As Reclining Chairs (AREA)
  • Medicinal Preparation (AREA)
CA002075982A 1990-02-21 1991-02-21 Insulin compositions Abandoned CA2075982A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0455/90 1990-02-21
DK045590A DK45590D0 (enExample) 1990-02-21 1990-02-21

Publications (1)

Publication Number Publication Date
CA2075982A1 true CA2075982A1 (en) 1991-08-22

Family

ID=8093754

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002075982A Abandoned CA2075982A1 (en) 1990-02-21 1991-02-21 Insulin compositions

Country Status (12)

Country Link
EP (1) EP0516704B1 (enExample)
JP (1) JPH05503940A (enExample)
AU (1) AU641991B2 (enExample)
CA (1) CA2075982A1 (enExample)
DE (1) DE69100626D1 (enExample)
DK (1) DK45590D0 (enExample)
HU (1) HUT63858A (enExample)
IE (1) IE910579A1 (enExample)
NZ (1) NZ237176A (enExample)
PT (1) PT96841A (enExample)
WO (1) WO1991012817A1 (enExample)
ZA (1) ZA911279B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
UA45321C2 (uk) * 1993-09-17 2002-04-15 Ново Нордіск А/С Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
CN101955527B (zh) 2003-08-05 2016-04-20 诺沃挪第克公司 新型胰岛素衍生物
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
WO2008034881A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
PL2254906T3 (pl) 2008-03-18 2017-04-28 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
HRP20180468T1 (hr) 2013-10-07 2018-05-04 Novo Nordisk A/S Novi derivat analoga inzulina
MY194504A (en) 2016-12-16 2022-11-30 Novo Nordisk As Insulin containing pharmaceutical compositions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2021009027A1 (en) 2019-07-12 2021-01-21 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE971500C (de) * 1950-11-22 1959-02-05 Organon Nv Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung
DE1107374B (de) * 1958-01-31 1961-05-25 Organon Nv Verfahren zur Herstellung eines Insulin-Praeparates

Also Published As

Publication number Publication date
AU7337891A (en) 1991-09-18
ZA911279B (en) 1991-10-30
IE910579A1 (en) 1991-08-28
JPH05503940A (ja) 1993-06-24
EP0516704B1 (en) 1993-11-10
DK45590D0 (enExample) 1990-02-21
AU641991B2 (en) 1993-10-07
DE69100626D1 (de) 1993-12-16
WO1991012817A1 (en) 1991-09-05
NZ237176A (en) 1991-12-23
HUT63858A (en) 1993-10-28
PT96841A (pt) 1991-11-29
HU9202721D0 (en) 1992-12-28
EP0516704A1 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
EP0516704B1 (en) Novel insulin compositions
DE3885317T2 (de) Makromolekulare Platin-Antitumorverbindungen.
US5456922A (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
KR890004687B1 (ko) 생물학적 활성 서방출성 조성물
CA1094549A (en) Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
JPH01502434A (ja) 新規インシュリン誘導体
EP0646379A1 (en) Insulin formulation
CZ85790A3 (en) Novel preparations containing associates of hyaluronic acid, and process for preparing thereof
AU2004251625A1 (en) Synthesis of high molecular weight iron-saccharidic complexes
HU227992B1 (en) Interferon conjugates, process for prepairing them, pharmaceutical compositions, containing them and use of them
EP0855913A1 (en) Iron dextran formulations
SA520420276B1 (ar) تركيبات صيدلية تحتوي على الأنسولين
EP2496213B1 (en) Pharmaceutical solution of non covalently bound albumin and acylated insulin
ZA200600846B (en) Novel insulin derivatives
JPS6011426A (ja) 糖尿病患者を治療する際に有用なガラクトシル−インシユリン複合体
HUT59942A (en) Process for producing glycozylized inzulines
CA1335924C (en) Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus
Enriquez et al. Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity
EP4591875A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
WO1981000674A1 (en) A process for preparing an injectable insulin preparation
EP1308155B1 (en) Injectable solution containing a colloid of iron and shark cartilage-derived chondroitin sulfate
RU2208440C2 (ru) Средство, обладающее противоанемической и иммуномодуляторной активностью
EP1620072B1 (en) Zinc-containing sustained-release composition, its preparation, and method for producing the same
EP2026789A2 (de) Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin
DE2646223C2 (enExample)

Legal Events

Date Code Title Description
FZDE Dead